Last reviewed · How we verify

Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion — Treatment Landscape & Competitive Intelligence

Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Rozlytrek entrectinib Roche High affinity nerve growth factor receptor 2019-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Roche · 1 drug in Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion:

Cite this brief

Drug Landscape (2026). Solid neoplasm with neurotrophic receptor tyrosine kinase gene fusion — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/solid-neoplasm-with-neurotrophic-receptor-tyrosine-kinase-gene-fusion. Accessed 2026-06-11.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing